What is Multiple Sclerosis?
Multiple Sclerosis is an unpredictable, autoimmune disease that affects the central nervous system. In Multiple Sclerosis, the body’s immune system produces cells and proteins (antibodies) that attack the fatty substance, myelin, which is responsible for protecting the nerve fibers.
How many people are affected by Multiple Sclerosis?
How will Multiple Sclerosis Market change in upcoming years?
The global therapeutic market of Multiple Sclerosis (MS) was estimated to be USD 23,344 million in 2017. The United States had the highest market size of Multiple Sclerosis in 2017, which accounts for ~71% of the total market.
Multiple Sclerosis (MS) is a multibillion-dollar market, flooded with many potential disease-modifying therapies (DMT), like Copaxone, Tecfidera, Gilenya, Tysabri, Avonex, Aubagio, Lemtrada, Ocrevus, Rebif, Betaseron, Extavia, Plegridy, Fampyra, and Zinbryta. All of these drugs, along with the upcoming therapies, have been considered for our market forecast calculations.
The DMTs used in the treatment of Multiple Sclerosis are mainly segmented into intravenous infusions (Tysabri and Lemtrada), injectables (Avonex, Copaxone, Rebif, Betaseron, Extavia, and Plegridy), and oral therapies (Aubagio, Tecfidera, and Gilenya). Traditionally, the treatment regimen was dominated by injectables and intravenous therapies, but gradually, oral therapies have taken up the majority of the percentage share, leading to becoming the most prescribed therapies.
With six approved DMTs [Avonex, Plegridy, Zinbryta, Fampyra (outside-US), Tysabri, and Tecfidera], it was noted that nearly 80% of Biogen’s revenue was generated by the company’s Multiple Sclerosis segment, which makes Biogen the strongest player in this market.
Increasing healthcare expenditure, rise in R&D activities, and awareness among patients about the treatment options will support the market growth for Multiple Sclerosis.
DelveInsight forecasts suggest that the launch of upcoming therapies and an increase in the drug-price of already approved therapies shall increase the Multiple Sclerosis market size in the eight pharmaceutical markets during the study period (2017–2030).
For free sample pages, request here @ Multiple Sclerosis market size
Scope of the Report
For free sample pages, request here @ Multiple Sclerosis Market Landscape
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/